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Abstract An anti-ubiquitin cross-reactive protein which mi-
grates more slowly (6.5 kDa) by SDS-PAGE than ubiquitin was
identified in African swine fever virus particles. This protein was
extracted into the detergent phase in Triton X-114 phase
separations, showing that it is hydrophobic, and was radiola-
belled with both [3H]palmitic acid and [32P]orthophosphate. This
indicates that the protein has a similar structure to the membrane
associated phosphatidyl ubiquitin described in baculovirus
particles. A similar molecule was found in vaccinia virus and
herpes simplex virus particles, suggesting that it may be a
component of uninfected cell membranes, which is incorporated
into membrane layers in virions during morphogenesis.
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1. Introduction
Ubiquitin is a 76 amino acid protein found in abundant
quantities in all eukaryotic cells. It is covalently coupled in
a multistep process, by enzymes of the ubiquitin conjugation
system, to Lys residues in substrate proteins. Multi-ubiquiti-
nated proteins generated by this process are targeted for deg-
radation by the proteasome (see [9,15] for reviews).
Although the ubiquitin system was thought to be involved
only in the degradation of cytosolic proteins, recent reports
have demonstrated ubiquitination of membrane proteins. Mis-
folded endoplasmic reticulum (ER) proteins, such as mutant
forms of the cystic ¢brosis transmembrane conductance regu-
lator [32], a mutant form of the yeast carboxypeptidase ysc Y
[11] and the yeast sec61p complex [2], are translocated out of
the ER, conjugated to ubiquitin and degraded by the protea-
some.
Immunogold electron microscopy shows gold particles cor-
responding to ubiquitin-protein conjugates in the endosome-
lysosome system of normal cells [22], as well as in similar
organelles in Epstein-Barr virus transformed lymphoblastic
cells [19] and in prion encephalopathies [20]. One reason for
ubiquitin-protein conjugates in the endosome-lysosome sys-
tems is that a number of cell surface receptors are ubiquiti-
nated on their cytoplasmic tails. For example, the growth
hormone receptor is ubiquitinated following ligand binding
and this signals internalisation and degradation within the
endosomal/lysosomal system [21,31]. Similarly ubiquitination
of the yeast cell surface K-factor exporter occurs at the cell
surface and is required for Ste6p entry into the vacuole [18].
Ubiquitination of the Ste2p pheromone receptor is obligatory
for internalisation into the vacuole [10].
Ubiquitin was thought to be exclusively a cytosolic protein
until a report described a modi¢ed form which was extracted
into the detergent phase by Triton X-114 (TX114) and was
present in the insect virus, baculovirus, particles [8]. This
modi¢cation was shown to be a lipid consisting of a phospha-
tidyl group containing two palmitate molecules linked via a
phosphate group to an internal Ser or Thr residue on ubiq-
uitin. This modi¢ed ubiquitin was localised on the cytosolic
face of the baculovirus outer membrane [8].
Neither a lipid modi¢ed form of ubiquitin nor this type of
protein modi¢cation had previously been described. However,
its discovery in baculovirus particles suggested that it may be
baculovirus or insect cell speci¢c and that the enzymes re-
quired for the modi¢cation are encoded by the baculovirus
genome or are only present in insect cells.
Here we report that a similar modi¢ed form of ubiquitin is
packaged into puri¢ed virions from several virus families
which contain lipid membranes. The discovery of this mole-
cule in virions which replicate in a range of di¡erent mamma-
lian cells suggests the modi¢ed ubiquitin is synthesised by the
host cell and may have a function in the physiology of unin-
fected cells. Possible roles for a lipid-modi¢ed, membrane-
associated ubiquitin in ubiquitination of membrane proteins
are discussed.
2. Materials and methods
2.1. Cells and viruses
Vero and BSC40 cell lines were grown in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) containing 10% foetal calf serum. Sf9 insect
cells were grown in Grace’s insect cell medium. The African swine
fever virus (ASFV) BA71V isolate [7] was grown in Vero cells, the
vaccinio virus VV WR strain in BSC40 cells and the baculovirus
AcNMPV in Sf9 cells. ASFV particles were puri¢ed from tissue cul-
ture cell supernatants by Percoll gradient centrifugation [5], vaccinia
virus particles were puri¢ed from cell extracts by caesium chloride
centrifugation [14] and baculovirus particles by sucrose gradient cen-
trifugation [8]. Puri¢ed herpes simplex virus particles and L particles
were a gift from Dr Frazer Rixon, Institute of Virology, Glasgow.
2.2. Radiolabelling of ASFV particles with [3H]palmitic acid and
[32P]orthophosphate
Vero cells in ¢ve 175 cm2 £asks were incubated for 12 h in DMEM
medium containing 50 WCi/ml of [32P]orthophosphate (NEN) supple-
mented with 2% foetal calf serum or 50 WCi/ml of [3H]palmitic acid
(NEN) supplemented with delipidated foetal calf serum. Radioactive
medium was removed and cells were infected with ASFV at a multi-
plicity of infection of 10 for 72 h. Radiolabelled ASFV particles were
puri¢ed from the extracellular medium by Percoll gradient centrifu-
gation.
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2.3. TX114 extractions
TX114 extractions were carried out as described [3]. Proteins from
aqueous and detergent phases were either precipitated with acetone
and redissolved in SDS-PAGE sample bu¡er or diluted 200-fold in 0.5
M NaCl, 20 mM Tris pH 7.5, 2 mM EDTA and immunoprecipitated
with anti-ubiquitin sera.
2.4. Immunoprecipitations and Western blotting
A cocktail of anti-ubiquitin sera (mouse monoclonals IG2E2 and
ID8, a gift from Dr L. Guarino, a mouse monoclonal against human
ubiquitin (Novacastra), and rabbit anti-ubiquitin sera (Dakopatts))
was used to immunoprecipitate ubiquitin from radiolabelled virion
proteins. Protein G Sepharose was used to pellet immunoprecipitates
and these were washed in 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM
EDTA, 0.02% NP40. Non-radioactive proteins were blotted onto Hy-
bond C membrane (Amersham) and blots were probed with rabbit
anti-ubiquitin sera (1/50). Bound antibodies were detected using
horseradish peroxidase (HRP) conjugated goat anti-rabbit sera fol-
lowed by enhanced chemiluminescence.
3. Results
3.1. A ubiquitin related protein of 6.5 kDa is packaged into
ASFV particles
We have previously identi¢ed a number of anti-ubiquitin
cross-reactive proteins present in puri¢ed ASFV particles.
One of these migrated with similar mobility to puri¢ed ubiq-
uitin [13]. To further characterise this molecule, we analysed,
by SDS-PAGE, ASFV proteins from puri¢ed virions and pu-
ri¢ed ubiquitin (Sigma). Blots were probed with anti-ubiquitin
sera and bound antibodies were detected using HRP conju-
gated secondary antibodies and enhanced chemiluminescence.
This showed that the smallest anti-ubiquitin cross-reactive
protein present in ASFV particles (Fig. 1B, lane 2) migrated
more slowly (V6.5 kDa) than puri¢ed ubiquitin (Fig. 1B, lane
1) (V5 kDa), suggesting that it is a modi¢ed form of ubiq-
uitin such as phosphatidyl ubiquitin found in baculovirus par-
ticles [8], a ubiquitin related protein with a slightly larger
molecular weight than ubiquitin, or ubiquitin conjugated to
a small peptide.
3.2. The ubiquitin related protein in ASFV particles is
hydrophobic and contains phosphate and palmitate groups
The phosphatidyl ubiquitin found in baculovirus particles is
extracted into the detergent phase by TX114 phase separation
because of the lipid modi¢cation [8]. To determine if the 6.5
kDa molecule present in ASFV particles might also be a lipid
modi¢ed form of ubiquitin, we lysed puri¢ed ASFV particles
in 1% TX114 and separated the proteins into detergent and
aqueous phases [3]. Proteins were separated by SDS-PAGE,
transferred to membranes and probed with anti-ubiquitin
antibodies. Puri¢ed ubiquitin was analysed in parallel (Fig.
1C). This showed that the 6.5 kDa protein from ASFV virions
was extracted into the detergent phase (Fig. 1C, lane 6) where-
as puri¢ed ubiquitin was present in the aqueous phase (Fig.
1C, lane 2). Thus, the 6.5 kDa protein present in ASFV par-
ticles may be a lipid modi¢ed form of ubiquitin similar to that
found in baculovirus particles. Multimers of ubiquitin are
found in cells and are also present in the puri¢ed ubiquitin
preparation. In Fig. 1C, lanes 1 and 2, di-ubiquitin is present
as a prominent band migrating with a mobility of about 16
kDa (Ub2, Fig. 1). An anti-ubiquitin cross-reactive protein of
about 18 kDa was detected in extracts from ASFV virion
proteins. This may be a di-ubiquitin form of the 6.5 kDa lipid
modi¢ed protein. Consistent with this, the 18 kDa protein was
largely extracted into the TX114 detergent phase (Fig. 1C,
lanes 4^6). To quantify the amount of the 6.5 kDa protein
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Fig. 1. A 6.5 kDa anti-ubiquitin immunoreactive protein present in
ASFV particles is extracted into the TX114 detergent phase. ASFV
particles were puri¢ed from tissue culture supernatants by Percoll
gradient centrifugation [5]. Virion proteins separated by 12.5% SDS-
PAGE and stained with silver are shown in A. B shows puri¢ed
ubiquitin (25 ng, Sigma, lane 1) and ASFV virion proteins (5 Wg,
lane 2) separated by 15% SDS-PAGE, blotted onto nitrocellulose
membranes and probed with anti-ubiquitin antisera. Bound antibod-
ies were detected with HRP conjugated secondary antibodies and
enhanced chemiluminescence (Amersham). C: Puri¢ed ubiquitin
(50 ng, lanes 1^3) and ASFV particles (10 Wg, lanes 4^6) were
treated with 1% TX114 then separated into aqueous and detergent
phases [3]. Proteins were precipitated with acetone and redissolved
in SDS-PAGE sample bu¡er. Lanes 1 and 4 show ubiquitin and
ASFV proteins which had not been treated with TX114. Lanes 2
and 5 show protein extracted into the aqueous phase from puri¢ed
ubiquitin (lane 2) and ASFV proteins (lane 5). Lanes 3 and 6 show
proteins extracted into the detergent phase from puri¢ed ubiquitin
(lane 3) and ASFV proteins (lane 6). Mono- and dimeric forms of
ubiquitin are labelled Ub and Ub2, UB6.5 and UB18 molecules re-
ferred to in the text are labelled. The positions of molecular weight
markers run in parallel are indicated.
Fig. 2. Immunoprecipitation of ASFV virion proteins labelled with
[3H]palmitic acid or [32P]orthophosphate with anti-ubiquitin sera.
Vero cells in 10U175 cm2 £asks were incubated for 12 h in medium
containing either [32P]orthophosphate (50 WCi/ml, lane 1) or
[3H]palmitic acid (50 WCi/ml, lane 2). Cells were then infected with
the BA71V ASFV isolate at a multiplicity of infection of 10 and
after 72 h virus was puri¢ed from the extracellular medium by Per-
coll gradient centrifugation [4]. Puri¢ed labelled virions were solubi-
lised in 1% TX114 then separated into aqueous and detergent
phases [3]. Proteins in the detergent phase were diluted 40-fold then
immunoprecipitated with a cocktail which included four di¡erent
anti-ubiquitin antisera. Immunoprecipitates were separated by 15%
SDS-PAGE and labelled proteins detected by autoradiography (lane
1) or £uorography (lane 2). The position of molecular weight
markers run in parallel is shown.
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present in ASFV particles, dilutions of known amounts of
ASFV proteins and of puri¢ed ubiquitin were separated by
SDS-PAGE and blotted. Blots were probed with anti-ubiqui-
tin sera and signals obtained compared by densitometry. This
showed that 1 Wg of puri¢ed ASFV virions contained 25^50
ng of the 6.5 kDa molecule (data not shown) corresponding to
2.5^5% of the total virion protein.
To further characterise the 6.5 kDa ubiquitin-like molecule,
we radioactively labelled ASFV virions with either
[32P]orthophosphate or [3H]palmitic acid. Vero cells were in-
cubated for 12 h in the presence of [32P]orthophosphate or
[3H]palmitic acid then infected with the BA71V strain of
ASFV. After 72 h virus was puri¢ed from the extracellular
medium [5]. Puri¢ed labelled virion proteins were lysed in 1%
TX114 for 1 h and proteins extracted into the detergent phase
were diluted 40-fold to reduce the concentration of detergent,
then immunoprecipitated with a cocktail of anti-ubiquitin
antisera. Immunoprecipitated proteins were separated by
SDS-PAGE and detected by autoradiography or £uorography
(Fig. 2). Proteins of 6.5 kDa were immunoprecipitated with
anti-ubiquitin sera from the TX114 detergent phase of both
the [32P]orthophosphate and [3H]palmitic acid labelled virion
proteins (Fig. 2, lanes 1 and 2) showing that the 6.5 kDa
detergent extractable ASFV anti-ubiquitin cross-reactive pro-
tein contains both phosphate and palmitate groups. This is
consistent with it being the same structure as the phosphatidyl
ubiquitin previously described in baculovirus particles puri¢ed
from infected insect cells [8].
3.3. A 6.5 kDa ubiquitin related molecule is present in puri¢ed
vaccinia virus and herpes simplex virus particles
We decided to analyse a number of other viruses which
contain lipid membranes to determine if a similar modi¢ed
form of ubiquitin may also be incorporated into these virions.
Puri¢ed vaccinia virus (VV) virions (a gift from Dr Sue
Jacobs), herpes simplex virus (HSV) virions and HSV-light
particles (a gift from Dr Frazer Rixon, Institute of Virology,
Glasgow), baculovirus particles (AcNMPV) and ASFV par-
ticles [5,8] were lysed in TX114. The proteins extracted into
the detergent phase were separated by SDS-PAGE, blotted
onto membranes and probed with anti-ubiquitin sera. An
anti-ubiquitin cross-reactive band of 6.5 kDa was detected
in puri¢ed VV and HSV preparations as well as in ASFV
and baculovirus particles (Fig. 3). This suggests that a lipid
modi¢ed form of ubiquitin similar to that present in ASFV
and baculovirus is also present in VV and HSV particles. The
amount of the UB18 protein recovered varies between di¡er-
ent virus preparations (compare for example Fig. 3, lanes 1^3
with 5^7).
4. Discussion
Several pieces of evidence suggest that the 6.5 kDa anti-
ubiquitin cross-reactive protein present in ASFV particles is
the same structure as the phosphatidyl ubiquitin previously
described only in baculovirus particles. Properties shared
with phosphatidyl ubiquitin include extraction into the
TX114 detergent phase, incorporation of [3H]palmitic acid
and [32P]orthophosphate, same mobility on SDS-PAGE and
cross-reactivity with anti-ubiquitin sera. Together these data
strongly suggest the molecules are the same structure. It is not
likely that the 6.5 kDa protein in ASFV particles is a ubiq-
uitin-related molecule which has a slightly larger molecular
weight than ubiquitin. Ubiquitin-related proteins character-
ised to date include SUMO which is 101 amino acids long
and UCRP which migrates at 15 kDa on SDS-PAGE [17].
However, none of the ubiquitin related molecules character-
ised to date is hydrophobic, nor do they contain palmitate or
phosphate groups. Also, although they are structurally re-
lated, they have relatively low amino acid identity compared
to ubiquitin and do not cross-react with anti-ubiquitin sera.
Our data show that the same type of modi¢ed ubiquitin
molecule is packaged into other virus particles which contain
lipid membranes including VV, a poxvirus and HSV.
These viruses are all from di¡erent families and although all
have large DNA genomes, it seems unlikely that all encode
enzymes required for the synthesis of a lipid modi¢ed ubiq-
uitin. Complete genome sequences are available for each of
these viruses [1,16,23,33] and there are no obvious encoded
enzymes in common which might be involved in lipid modi¢-
cation of ubiquitin. It is more likely that the lipid modi¢ed
ubiquitin is a host cell molecule which is present in cell mem-
branes and is packaged into the envelope of virus particles
during virion morphogenesis. ASFV, VV, HSV and baculovi-
rus all have di¡erent mechanisms of morphogenesis and in-
corporate host membranes derived from di¡erent cellular
compartments into their virions. Thus, VV incorporates mem-
branes from the intermediate compartment and from the
trans-Golgi network [28,29]. HSV particles are thought to
acquire their envelopes by budding through the ER-inner nu-
clear membranes [25,30], although a recent report suggests
that HSV particles lose this nuclear membrane and gain their
envelope from the trans-Golgi network [4]. ASFV incorpo-
rates membranes from the endoplasmic reticulum and plasma
membrane [6,27] and baculovirus particles acquire their enve-
lopes from the plasma membrane [26]. The implication is that
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Fig. 3. A 6.5 kDa, TX114 detergent extractable, anti-ubiquitin reac-
tive protein is present in puri¢ed vaccinia virus and herpes simplex
virus virions. Puri¢ed vaccinia virus (intracellular mature form, VV,
10 Wg, lane 1), ASFV (10 Wg, lanes 2 and 5), baculovirus
(AcNMPV, 10 Wg, lane 3), herpes simplex virus (HSV, 10 Wg, lane
6) and HSV-light particles (HSV-L, 10 Wg, lane 7) were solubilised
in 1% TX114 then proteins separated into aqueous and detergent
phases. Proteins were precipitated with acetone from the detergent
phase. These detergent extracted virion proteins and puri¢ed ubiqui-
tin (25 ng) were separated by 15% SDS-PAGE, blotted onto nitro-
cellulose and reacted with anti-ubiquitin antisera (Dakopatts).
Bound antibodies were detected using horseradish peroxidase conju-
gated secondary antibody and enhanced chemiluminescence. The po-
sition of molecular weight markers run in parallel is shown.
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if the lipid modi¢ed ubiquitin incorporated into virus particles
is from host cells, this must be present in several di¡erent
membrane compartments. Phospholipids are synthesised in
the ER and transported from there to other membrane com-
partments in cells. Thus, the presence of lipid modi¢ed ubiq-
uitin in virus particles which derive their membranes from
several di¡erent intracellular compartments, is consistent
with synthesis of this molecule in the ER and transport
from there to other compartments.
A lipid modi¢ed ubiquitin has not been reported in unin-
fected cells. There may be several reasons for this. First, it
may represent a small proportion of the total ubiquitin and
might only be detected if puri¢ed away from the bulk of
cellular ubiquitin by, for example, purifying the membrane
fraction. Secondly, it may be susceptible to degradation by
phospholipases and therefore di⁄cult to isolate. It may be
easier to detect in puri¢ed virions because it is concentrated
in these particles and protected from degradation by cellular
enzymes.
4.1. Possible functions of a membrane associated, lipid modi¢ed
form of ubiquitin
One implication from our results is that a phosphatidyl
modi¢ed ubiquitin may have a role in normal cell physiology.
As discussed in the introduction, ubiquitin has a role in tar-
geting misfolded ER proteins for degradation by the protea-
some and in internalisation of membrane receptors. A likely
role for a membrane attached ubiquitin is as a source of
ubiquitin for conjugation to membrane proteins. Another pos-
sible function for a membrane anchored ubiquitin is as a
novel mechanism for membrane attachment of proteins. Since
enzymes (de-ubiquitinating enzymes or DUBS) which remove
ubiquitin from proteins exist [17,24], this type of membrane
attachment could be reversible. The modi¢ed ubiquitin incor-
porated into virus particles may either have a speci¢c function
during virus replication or it may merely be incorporated as a
consequence of being in cell membranes that are incorporated
in the virus structure. Possible roles during virus replication
are as a source of ubiquitin for conjugation to host or virion
proteins so that they are targeted for degradation. This may,
for example, be required as part of the virion uncoating proc-
ess or to activate gene transcription. Interestingly, ASFV en-
codes a ubiquitin conjugating enzyme (UBCv) which is also
packaged into virus particles [12]. This suggests that UBCv
may conjugate ubiquitin to either virus or host proteins early
during the virus replication cycle. Possibly the modi¢ed ubiq-
uitin in virus particles is used for this purpose.
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